Gland Pharma appoints Ajay Sahni as CEO of Singapore subsidiary
- Management change
Gland Pharma (NSE: GLAND) has appointed Ajay Sahni as Chief Executive Officer of Gland Pharma International Pte. Ltd., its wholly owned subsidiary in Singapore, effective 2 Nov 2026, it said in a filing on 30 Oct 2026. Sahni will also be responsible for the Cenexi business, a wholly owned step-down subsidiary, and will report to the CEO of Gland Pharma Limited.
Sahni's roles and background
Sahni has over 36 years of experience in FMCG and pharmaceutical industries, covering financial management, business development and general management, according to the filing. His previous roles include managing director of Pinewood Healthcare Ltd in Ireland, managing director of Wockhardt Bio AG in Switzerland, and president of Wockhardt France SAS and its subsidiaries.
Sign up to continue reading
Create a free account to read the rest of this article and the analysis that follows.
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
